Identification of Genes Potentially Associated with Melanoma Tumorigenesis Through Co-Expression Network Analysis

References

• Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20(11):1366–1379. doi:10.1080/15384047.2019.1640032
   PubMed Web of Science ®Google Scholar
• Tripp MK, Watson M, Balk SJ, Swetter SM, Gershenwald JE. State of the science on prevention and screening to reduce melanoma incidence and mortality: the time is now. CA Cancer J Clin. 2016;66(6):460–480. doi:10.3322/caac.21352
   PubMed Web of Science ®Google Scholar
• Wei CY, Zhu MX, Lu NH, et al. Bioinformatics-based analysis reveals elevated MFSD12 as a key promoter of cell proliferation and a potential therapeutic target in melanoma. Oncogene. 2019;38(11):1876–1891. doi:10.1038/s41388-018-0531-6
   PubMed Web of Science ®Google Scholar
• Hutchinson KE, Lipson D, Stephens PJ, et al. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res. 2013;19(24):6696–6702. doi:10.1158/1078-0432.CCR-13-1746
   PubMed Web of Science ®Google Scholar
• Andrews MC, Cursons J, Hurley DG, et al. Systems analysis identifies miR-29b regulation of invasiveness in melanoma. Mol Cancer. 2016;15(1):72. doi:10.1186/s12943-016-0554-y
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet. 2018;392(10151):971–984. doi:10.1016/S0140-6736(18)31559-9
   PubMed Web of Science ®Google Scholar
• Choudhary S, Pradhan D, Khan NS, Singh H, Thomas G, Jain AK. Decoding psoriasis: integrated bioinformatics approach to understand hub genes and involved pathways. Curr Pharm Des. 2020;26(29):3619–3630. doi:10.2174/1381612826666200311130133
   PubMed Web of Science ®Google Scholar
• Harripaul R, Vasli N, Mikhailov A, et al. Mapping autosomal recessive intellectual disability: combined microarray and exome sequencing identifies 26 novel candidate genes in 192 consanguineous families. Mol Psychiatry. 2018;23(4):973–984. doi:10.1038/mp.2017.60
   PubMed Web of Science ®Google Scholar
• Avelar RA, Ortega JG, Tacutu R, et al. A multidimensional systems biology analysis of cellular senescence in aging and disease. Genome Biol. 2020;21(1):91. doi:10.1186/s13059-020-01990-9
   PubMed Web of Science ®Google Scholar
• Oerton E, Bender A. Concordance analysis of microarray studies identifies representative gene expression changes in Parkinson’s disease: a comparison of 33 human and animal studies. BMC Neurol. 2017;17(1):58. doi:10.1186/s12883-017-0838-x
   PubMed Web of Science ®Google Scholar
• Xu C, Meng LB, Duan YC, et al. Screening and identification of biomarkers for systemic sclerosis via microarray technology. Int J Mol Med. 2019;44(5):1753–1770. doi:10.3892/ijmm.2019.4332
   PubMed Web of Science ®Google Scholar
• Ball SL, Cockell SJ, Wilson JA, Mann DA, Fisher AJ. Microarray analysis of primary epithelial and fibroblast cells in chronic rhinosinusitis without nasal polyps. Rhinology. 2020;58(6):581–587. doi:10.4193/Rhin19.319
   PubMed Web of Science ®Google Scholar
• Wei CY, Zhu MX, Yang YW, et al. Downregulation of RNF128 activates Wnt/beta-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma. J Hematol Oncol. 2019;12(1):21. doi:10.1186/s13045-019-0711-z
   PubMed Web of Science ®Google Scholar
• Luan W, Ding Y, Yuan H, et al. Long non-coding RNA LINC00520 promotes the proliferation and metastasis of malignant melanoma by inducing the miR-125b-5p/EIF5A2 axis. J Exp Clin Cancer Res. 2020;39(1):96. doi:10.1186/s13046-020-01599-7
   PubMed Web of Science ®Google Scholar
• Su W, Guan Y, Huang B, et al. Bioinformatic analysis reveals hub genes and pathways that promote melanoma metastasis. BMC Cancer. 2020;20(1):863. doi:10.1186/s12885-020-07372-5
   PubMed Web of Science ®Google Scholar
• Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–210. doi:10.1093/nar/30.1.207
   PubMed Web of Science ®Google Scholar
• Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41(Database issue):D991–5. doi:10.1093/nar/gks1193
   PubMed Web of Science ®Google Scholar
• Da huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13. doi:10.1093/nar/gkn923
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D13. doi:10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• Bandettini WP, Kellman P, Mancini C, et al. MultiContrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn Reson. 2012;14:83. doi:10.1186/1532-429X-14-83
   PubMed Web of Science ®Google Scholar
• Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8 Suppl 4:S11. doi:10.1186/1752-0509-8-S4-S11
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e10. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Han H, Cho JW, Lee S, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res. 2018;46(D1):D380–D86. doi:10.1093/nar/gkx1013
   PubMed Web of Science ®Google Scholar
• Wagner AH, Coffman AC, Ainscough BJ, et al. DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res. 2016;44(D1):D1036–44. doi:10.1093/nar/gkv1165
   PubMed Web of Science ®Google Scholar
• Marzagalli M, Ebelt ND, Manuel ER. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin Cancer Biol. 2019;59:236–250. doi:10.1016/j.semcancer.2019.08.002
   PubMed Web of Science ®Google Scholar
• Wolf Y, Bartok O, Patkar S, et al. UVB-induced tumor heterogeneity diminishes immune response in melanoma. Cell. 2019;179(1):219–35 e21. doi:10.1016/j.cell.2019.08.032
   PubMed Web of Science ®Google Scholar
• Gartrell-Corrado RD, Chen AX, Rizk EM, et al. Linking transcriptomic and imaging data defines features of a favorable tumor immune microenvironment and identifies a combination biomarker for primary melanoma. Cancer Res. 2020;80(5):1078–1087. doi:10.1158/0008-5472.CAN-19-2039
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kurupati R, Liu L, et al. Enhancing CD8(+) T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell. 2017;32(3):377–91e9. doi:10.1016/j.ccell.2017.08.004
   PubMed Web of Science ®Google Scholar
• Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res. 2018;24(6):1260–1270. doi:10.1158/1078-0432.CCR-17-2267
   PubMed Web of Science ®Google Scholar
• Gupta R, Janostiak R, Wajapeyee N. Transcriptional regulators and alterations that drive melanoma initiation and progression. Oncogene. 2020;39(48):7093–7105. doi:10.1038/s41388-020-01490-x
   PubMed Web of Science ®Google Scholar
• Tokunaga R, Zhang W, Naseem M, et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy. Cancer Treat Rev. 2018;63:40–47. doi:10.1016/j.ctrv.2017.11.007
   PubMed Web of Science ®Google Scholar
• Raskin L, Fullen DR, Giordano TJ, et al. Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis. J Invest Dermatol. 2013;133(11):2585–2592. doi:10.1038/jid.2013.197
   PubMed Web of Science ®Google Scholar
• Kabbarah O, Nogueira C, Feng B, et al. Integrative genome comparison of primary and metastatic melanomas. PLoS One. 2010;5(5):e10770. doi:10.1371/journal.pone.0010770
   PubMed Web of Science ®Google Scholar
• Yan BY, Garcet S, Gulati N, et al. Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin. Exp Dermatol. 2019;28(1):35–44. doi:10.1111/exd.13805
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12(2):121–127. doi:10.1016/s1074-7613(00)80165-x
   PubMed Web of Science ®Google Scholar
• Bagheri H, Pourhanifeh MH, Derakhshan M, et al. CXCL-10: a new candidate for melanoma therapy? Cell Oncol (Dordr). 2020;43(3):353–365. doi:10.1007/s13402-020-00501-z
   PubMed Web of Science ®Google Scholar
• Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89(2):207–215. doi:10.1038/icb.2010.158
   PubMed Web of Science ®Google Scholar
• Antonicelli F, Lorin J, Kurdykowski S, et al. CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo. Br J Dermatol. 2011;164(4):720–728. doi:10.1111/j.1365-2133.2010.10176.x
   PubMed Web of Science ®Google Scholar
• Hsieh MF, Lai SL, Chen JP, et al. Both CXCR3 and CXCL10/IFN-inducible protein 10 are required for resistance to primary infection by dengue virus. J Immunol. 2006;177(3):1855–1863. doi:10.4049/jimmunol.177.3.1855
   PubMed Web of Science ®Google Scholar
• Gorbachev AV, Kobayashi H, Kudo D, et al. CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol. 2007;178(4):2278–2286. doi:10.4049/jimmunol.178.4.2278
   PubMed Web of Science ®Google Scholar
• Menke J, Zeller GC, Kikawada E, et al. CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease. J Am Soc Nephrol. 2008;19(6):1177–1189. doi:10.1681/ASN.2007111179
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA. 2010;107(9):4275–4280. doi:10.1073/pnas.0915174107
   PubMed Web of Science ®Google Scholar
• Verbeke H, Geboes K, Van Damme J, Struyf S. The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochim Biophys Acta. 2012;1825(1):117–129. doi:10.1016/j.bbcan.2011.10.008
   PubMed Web of Science ®Google Scholar
• Nagpal ML, Davis J, Lin T. Overexpression of CXCL10 in human prostate LNCaP cells activates its receptor (CXCR3) expression and inhibits cell proliferation. Biochim Biophys Acta. 2006;1762(9):811–818. doi:10.1016/j.bbadis.2006.06.017
   PubMed Web of Science ®Google Scholar
• Li G, Tian L, Hou JM, et al. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors. Clin Cancer Res. 2005;11(11):4217–4224. doi:10.1158/1078-0432.CCR-04-2117
   PubMed Web of Science ®Google Scholar
• Zhao M, Ma Q, Xu J, et al. Combining CXCL10 gene therapy and radiotherapy improved therapeutic efficacy in cervical cancer HeLa cell xenograft tumor models. Oncol Lett. 2015;10(2):768–772. doi:10.3892/ol.2015.3281
   PubMed Web of Science ®Google Scholar
• Zumwalt TJ, Arnold M, Goel A, Boland CR. Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration. Oncotarget. 2015;6(5):2981–2991. doi:10.18632/oncotarget.3205
   PubMed Web of Science ®Google Scholar
• Barash U, Zohar Y, Wildbaum G, et al. Heparanase enhances myeloma progression via CXCL10 downregulation. Leukemia. 2014;28(11):2178–2187. doi:10.1038/leu.2014.121
   PubMed Web of Science ®Google Scholar
• Noman MZ, Berchem G, Janji B. Targeting autophagy blocks melanoma growth by bringing natural killer cells to the tumor battlefield. Autophagy. 2018;14(4):730–732. doi:10.1080/15548627.2018.1427398
   PubMed Web of Science ®Google Scholar
• Zhao N, Dang H, Ma L, et al. Intratumoral gammadelta T-Cell Infiltrates, Chemokine (C-C Motif) Ligand 4/Chemokine (C-C Motif) Ligand 5 Protein expression and survival in patients with Hepatocellular carcinoma. Hepatology. 2021;73(3):1045–1060. doi:10.1002/hep.31412
   PubMed Web of Science ®Google Scholar
• Luque I, Gelinas C. Rel/NF-kappa B and I kappa B factors in oncogenesis. Semin Cancer Biol. 1997;8(2):103–111. doi:10.1006/scbi.1997.0061
   PubMed Web of Science ®Google Scholar
• Gilmore TD, Koedood M, Piffat KA, White DW. Rel/NF-kappaB/IkappaB proteins and cancer. Oncogene. 1996;13(7):1367–1378.
   PubMedGoogle Scholar
• Huang S, DeGuzman A, Bucana CD, Fidler IJ. Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res. 2000;6(6):2573–2581.
   PubMed Web of Science ®Google Scholar
• Antonczyk A, Krist B, Sajek M, et al. Direct inhibition of IRF-dependent transcriptional regulatory mechanisms associated with disease. Front Immunol. 2019;10:1176. doi:10.3389/fimmu.2019.01176
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol. 2001;19:623–655. doi:10.1146/annurev.immunol.19.1.623
   PubMed Web of Science ®Google Scholar
• Limagne E, Thibaudin M, Nuttin L, et al. Trifluridine/tipiracil plus oxaliplatin improves PD-1 blockade in colorectal cancer by inducing immunogenic cell death and depleting macrophages. Cancer Immunol Res. 2019;7(12):1958–1969. doi:10.1158/2326-6066.CIR-19-0228
   PubMed Web of Science ®Google Scholar
• Hong YS, Kim SY, Lee JS, et al. Oxaliplatin-based adjuvant chemotherapy for rectal cancer after preoperative chemoradiotherapy (ADORE): long-term results of a randomized controlled trial. J Clin Oncol. 2019;37(33):3111–3123. doi:10.1200/JCO.19.00016
   PubMed Web of Science ®Google Scholar
• Minami Y, Sasaki T, Bochimoto H, et al. Prostaglandin I2 analog suppresses lung metastasis by recruiting pericytes in tumor angiogenesis. Int J Oncol. 2015;46(2):548–554. doi:10.3892/ijo.2014.2783
   PubMed Web of Science ®Google Scholar